JBCHEPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | JBCHEPHARM | Market Cap | 32,809 Cr. | Current Price | 2,043 ₹ | High / Low | 2,195 ₹ |
| Stock P/E | 45.1 | Book Value | 238 ₹ | Dividend Yield | 0.76 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 2,004 ₹ | DMA 200 | 1,872 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 54.9 | MACD | 3.49 | Volume | 1,49,338 | Avg Vol 1Wk | 2,54,920 |
| Low price | 1,495 ₹ | High price | 2,195 ₹ | PEG Ratio | 1.89 | Debt to equity | 0.01 |
| 52w Index | 78.4 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 30.1 |
📊 Chart & Indicators
- Current price (₹2,043) is above DMA 50 (₹2,004) and DMA 200 (₹1,872), showing bullish momentum.
- RSI at 54.9 indicates balanced momentum, neither overbought nor oversold.
- MACD at 3.49 confirms mild bullish crossover.
- Bollinger Bands: price near upper band, suggesting strong momentum but risk of pullback.
- Volume (1.49 Lakh) below average (2.54 Lakh), showing reduced participation.
🎯 Entry & Exit Zones
- **Entry Zone:** ₹2,000 – ₹2,030 (near DMA 50 support).
- **Exit Zone:** ₹2,150 – ₹2,195 (recent high resistance).
- **Stop-Loss:** Below ₹1,980 (DMA 50 breakdown risk).
📈 Trend Status
- The stock is **consolidating with bullish undertone**.
- Sustaining above ₹2,030 could trigger further upside toward ₹2,150+.
✅ Positive
- Strong ROCE (25.9%) and ROE (20.2%).
- EPS at ₹46.5 with consistent growth.
- Very low debt-to-equity ratio (0.01).
- FII holdings increased (+1.45%), showing foreign investor confidence.
- Price trading above both 50 DMA and 200 DMA.
⚠️ Limitation
- Volume below average, showing reduced participation.
- Quarterly PAT declined (₹200 Cr. → ₹179 Cr.).
- DII holdings decreased (-1.97%).
- P/E (45.1) higher than industry average (30.1), suggesting premium valuation.
- Dividend yield modest at 0.76%.
📉 Company Negative News
- Sequential decline in quarterly profits.
- Domestic institutional holdings decreased.
- Weak short-term momentum despite strong fundamentals.
📈 Company Positive News
- Quarterly profit variance (+14.6%) shows improving earnings consistency.
- Strong fundamentals with high ROCE and ROE.
- Price performance supported by 52-week index gain of 78.4%.
🏭 Industry
- Industry PE at 30.1 vs JBCHEPHARM PE at 45.1, indicating premium valuation.
- Pharma sector outlook remains positive with steady demand and defensive positioning.
🔎 Conclusion
JBCHEPHARM is consolidating near support levels with strong fundamentals but weak short-term momentum due to low volume. Entry near ₹2,000–₹2,030 is favorable for cautious traders, with exits around ₹2,150–₹2,195. Trend remains consolidative with bullish undertone, requiring stronger volume and momentum indicators for sustained breakout.
Would you like me to extend this into a swing trade overlay comparing JBCHEPHARM with peers like Divi’s Lab, Sun Pharma, and Cipla for sector benchmarking?